3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Prostatic Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
3
Ovarian Neoplasms
2
mCRPC
1
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Hepatoblastoma
1
Hemangiosarcoma
1
Extensive Stage Lung Small Cell Carcinoma
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma
1
Interventions
Dexamethasone
116
daratumumab
70
Lenalidomide
66
Bortezomib
56
pomalidomide
46
carfilzomib
40
Cyclophosphamide
34
Specimen Handling
30
Calcium Dobesilate
30
Biopsy
27
Magnetic Resonance Spectroscopy
25
belantamab mafodotin
21
isatuximab
19
fludarabine
18
talquetamab
16
iberdomide
16
Melphalan
15
dexamethasone acetate
13
dexamethasone 21-phosphate
13
auricularum
13
fludarabine phosphate
11
selinexor
10
elotuzumab
10
tocilizumab
9
X-Rays
8
Nivolumab
8
Whole-Body Irradiation
7
Sirolimus
7
trametinib
6
Mycophenolic Acid
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
talazoparib
×
90 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled